Since SRS became a standard option for the treatment of melanoma brain metastases while immunotherapy (immune checkpoint inhibitors) and targeted therapy (BRAF/MEK inhibitors) significantly improved outcomes and prognosis of patients with advanced melanoma, over past years concurrent administration of SRS with immunotherapy or targeted therapy has been intensively evaluated in clinical management of melanoma brain metastases [35, 36]. This evidence concerns the gene BRAF and melanoma.